P1.03-036 Adjuvant Chemotherapy with Uracil-Tegafur for Pathological T1aN0M0 Lung Adenocarcinoma with Lymphatic Vessel Invasion
نویسندگان
چکیده
منابع مشابه
Adjuvant chemotherapy with tegafur/uracil administration after transcatheter arterial chemoembolization for advanced hepatocellular carcinoma.
Although transcatheter arterial chemoembolization (TACE) is considered to be an effective treatment for advanced hepatocellular carcinoma (HCC), it is difficult to achieve complete necrosis by TACE alone due to incomplete embolization and tumor angiogenesis. Recent studies have shown that tegafur/uracil (UFT) inhibits tumor angiogenesis in several cancer types. Therefore, this study was conduct...
متن کاملOral Adjuvant Chemotherapy with S-1 or Uracil-tegafur versus Surgery Alone in Patients with Biliary Tract Cancer
Objective: We compared the influence of postoperative adjuvant chemotherapy with oral anticancer drugs (S-1 or uracil-tegafur [UFT]) and the influence of surgery alone on overall survival (OS) and disease-free survival (DFS) in patients with biliary tract cancer. Methods: This retrospective study included 108 patients with gallbladder cancer (n=22) or bile duct cancer (n=86), who underwent cura...
متن کاملAdjuvant Oral Uracil-Tegafur with Leucovorin for Colorectal Cancer Liver Metastases: A Randomized Controlled Trial
BACKGROUND The high recurrence rate after surgery for colorectal cancer liver metastasis (CLM) remains a crucial problem. The aim of this trial was to evaluate the efficacy of adjuvant therapy with uracil-tegafur and leucovorin (UFT/LV). METHODS In the multicenter, open-label, phase III trial, patients undergoing curative resection of CLM were randomly assigned in a 1:1 ratio to either the UF...
متن کاملA Phase II Study of Adjuvant Chemotherapy of Tegafur-Uracil for Patients with Breast Cancer with HER2-negative Pathologic Residual Invasive Disease After Neoadjuvant Chemotherapy.
BACKGROUND There is no consensus on the need for adjuvant chemotherapy for patients with pathological residual invasive breast cancer (non-pCR) after neoadjuvant chemotherapy (NAC). We evaluated the tolerability and safety of tegafur-uracil (UFT) as adjuvant chemotherapy for patients with human epidermal growth factor receptor 2-negative breast cancer that resulted in non-pCR after NAC. PATIE...
متن کامل[The prognostic significance of lymphatic vessel and blood vessel invasion in peripherally located adenocarcinoma of the lung].
要 旨:末 梢 型 肺 腺 癌 の 脈 管 侵 襲 と予 後 と の 関 連 を検 討 し た.1989年1月 か ら1999年12月 ま で に 切 除 し た 末 梢 型 肺 腺 癌344例 全 例 を対 象 と した.平 均 観 察 期 間 は42カ 月,5生 率 は68.2%で あ っ た.脈 管 侵 襲 別 の5生 率 は, ly0v0群96%, ly0v1群75%,ly1v0群75%, ly1v1群65%, ly2, 3 and/or v2, 3(以 下lyv2-3)群37%で, ly0v0 群 の 予 後 は 明 らか に 良 好 で あ っ た.ly0v0症 例 の97%はI期 症 例 で,ly0v0症 例 はIA期 症 例 の51%, IB期 症 例 の23%を 占 め た が,IIA期 以 上 の 症 例 に は わ ず か で あ っ た.IA期 症 例 の 脈...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Oncology
سال: 2017
ISSN: 1556-0864
DOI: 10.1016/j.jtho.2017.09.840